Clinical Study Of Disulfiram To Reduce HIV Reservoir

Image via WikipediaThis caught my eye while scanning health news, Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals.

This ClinicalTrials.gov notice provides robust details about the research study, which is actively recruiting participants.

I find the basis for the study pretty interesting:

"Our primary hypothesis is that disulfiram will reduce the latent reservoir of HIV-1 in patients on highly active antiretroviral therapy (HAART). Theoretically, disulfiram will force HIV to replicate (grow) and thus result in the death of the infected cell. Standard antiretroviral drugs should prevent new cells from becoming infected. The end result of this process is that the total amount of HIV in the body will decline over time."

Return Home: http://drughealth.blogspot.com/

Preventive Anti-HIV Drug Use - Cautious Prescribing

The CDC just published, Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men.

In a nutshell:

The report provides interim guidance to health-care providers based on the reported results of the trial, which indicated that tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling.

You might also be interested in:
The CDC on Pre-Exposure Prophylaxis (PrEP)

Return Home: http://drughealth.blogspot.com/
The Health, Drug, Prescription, and GMP Supersite Gift Store

Future Pills - Drugs, Devices, and More

An interesting intersection of drugs and medical devices, reported in this LA Times article, Smarter Pills - BEEP! BEEP! BEEP! This is your medicine. It's time for another dose.

In a nutshell,

"The goal: new devices to help people take their meds on time and improve the results coming out of clinical trials for new drugs."

Return Home: http://drughealth.blogspot.com/

New Gel Reduces HIV Infection in Women

Updated July 1, 2025

The report of the results of Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial. 

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors

Univ of CA CMCR - Evidence Cannabis Is A Promising Treatment

Image via Wikipedia

The Center for Medicinal Cannabis Research: Report to the California Legislature (2010) - pdf reports:

"The CMCR has successfully conducted the first clinical trials of smoked cannabis in the United States in more than 20 years. As a result of this program of systematic research, we now have reasonable evidence that cannabis is a promising treatment in selected pain syndromes caused by injury or diseases of the nervous system, and possibly for painful muscle spasticity due to multiple sclerosis."

Learn More:
Understanding Marijuana: A New Look at the Scientific Evidence

Return Home: http://drughealth.blogspot.com/
The Health, Drug, Prescription, and GMP Supersite Gift Store

HIV AIDS - 97 US Medicines in Testing - PharmaTimes

Image via Wikipedia

This is a really nice snapshot of some of the clinical testing going on in the HIV AIDS field, PhRMA's Pharmaceutical Researchers Are Testing 97 Medicines And Vaccines for HIV and Related Conditions. The article provides a quick overview for medicines grouped by:

1. Anticancer
2. Antiviral
3. Gene therapy
4. Immunomodulators
5. Vaccines
6. Other

Previous Posts: Abzymes Pinpoint The HIV Achilles Heel 109 HIV Drugs And Vaccines Under Development Listen To People With AIDS and HIV (audio)

Return Home: http://drughealth.blogspot.com/ 

Primer On Clinical Drug Studies

Updated May 30, 2025

The original link broke.

You might also like this podcast from the FDA on Clinical Trial Basics:

https://www.youtube.com/watch?v=brYANNYW8IY

---  the original post follows below  ---

Watch this free video and learn about, "Drug Studies: Who, What, When, Where, and Why."

UCTV says, "Almost every American takes a drug every day; many take three or more. This series presented by the UCSF Osher Lifelong Learning Institute explores your medicine, your health and your money. In this episode join John Flaherty, director of medical affairs at Gilead Science, Inc, as he explores the use of drug studies. Series: "UCSF Mini Medical School for the Public" [9/2007] [Health and Medicine] [Show ID: 13072] " 

Related Posts: Global Outsourcing - Clinical Drug Trials - Hot Debate 

Return Home: http://drughealth.blogspot.com/ 

Global Outsourcing - Clinical Drug Trials - Hot Debate

Global outsourcing continues, and fuels some interesting debate, as evidenced by this recent New England Journal of Medicine (NEJM) article, "Ethical and Scientific Implications of the Globalization of Clinical Research." Of current interest, one of the author's name, Robert Califf, comes up as a candidate to lead the FDA. In CenterWatch's Clinicial Trials Today post, "Duke, NEJM Study Renews Debate on Global Outsourcing, they say "the NEJM study findings support common criticisms that trial participants in developing countries are often less informed and unduly influenced by the promise of money or medical care in return for participating in a study. While critics of clinical research in emerging areas (comprising 16% of total global clinical trials) can deride the informed consent process there, the West is no stranger to these problems." 

Related Posts: FDA Draft Guidance - Drug Supply Chain and SNIs FDA - Global Drug Supply Chain Needs Better Oversight Prescription Drug Reimportation and Safety - Both Presidential Candidates Support It 

Return Home: http://drughealth.blogspot.com/ 

Wow - FDA OKs Stem Cell Trial - This is a red letter day!

I'm thrilled to see some momentum gaining in this potentially rich area of clinical research. The U.S. Food and Drug Administration has granted clearance for Geron Corp. to begin trials for the world's first study of a human embryonic stem cell-based therapy for people. Geron said it will begin a Phase I multicenter trial designed to establish the safety of its treatment, currently referred to as "GRNOPC1," in patients with complete Grade A subacute thoracic spinal cord injuries. Read more details in this Medical News Today article, US Approves First Trial Of Embryonic Stem Cells.

I'm of the opinion that stem cell research has been stifled for way too long, and it's good to see the appearance of these studies. What's your opinion?

Return Home: http://drughealth.blogspot.com/
The Health, Drug, Prescription, and GMP Supersite Gift Store
Return to Mobile Home: http://drughealth.mofuse.mobi/

FDA Data Guidance - When patients withdraw from clinical trials

How do you handle data when patients withdraw from clinical trials? For a well-written summary, read this post on the FDA Law Blog, "New Guidance Documents Available for When Subjects Withdraw from Clinical Trials." Thanks to Susan Matthees for writing this easily digestible article on the subject that includes links to the two guidance documents.

View more FDA Guidance Documents (free)

Return Home: http://drughealth.blogspot.com/
The Health, Drug, Prescription, and GMP Supersite Gift Store
Return to Mobile Home: http://drughealth.mofuse.mobi/

Trackback url for the cited post above:
http://www.typepad.com/t/trackback/2294638/36853634